LEGAL AND REGULATORY FRAMEWORK Sample Clauses

LEGAL AND REGULATORY FRAMEWORK. This Policy is issued pursuant to, and in compliance with the requirements of Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments and amending Directive 2002/92/EC and Directive 2011/61/EU (“MiFID II”), the Law of the Republic of Cyprus No 87(I)/2017 regarding the provision of investment services, the exercise of investment activities and the operation of regulated markets which transposed MiFID II into Cyprus legislation and the Investment Services and Activities and Regulated Markets Law of the Republic of Cyprus Law No 144(I)/2007 to the extent it remains applicable after coming into force of XxXXX XX. Furthermore, this Policy complies with Section 9 of the Questions and Answers Document of the European Securities and Markets Authority (“ESMA”) issued on 11 October 2016 with reference ESMA/2016/1454 with respect to the provision of CFDs and other speculative products to retail investors. In this Policy, we collectively refer to all the above legislations, regulations and guidelines as “Regulations”.
Sample 1Sample 2
AutoNDA by SimpleDocs
LEGAL AND REGULATORY FRAMEWORK. The legal and regulatory framework of national and international jurisdictions with regards to blockchain technology is in development and subject to changes. Regulatory measures might impact Tokens and/or Interface negatively in a number of ways. The Company may cease to operate in a country or even abandon certain features of the project if regulatory action or changes in laws or regulations make it illegal to operate in such country or it is commercially desirable to obtain the necessary regulatory approval(s) to operate in such country. This includes, in particular, the risk that the Tokens cannot be used or can no longer be used for its intended purpose due to changes in the legal or regulatory framework and may become unusable under certain circumstances. The Company therefore does not guarantee that the Tokens are legal in all jurisdictions. The Purchaser solely bears all legal or financial consequences if the Tokens are considered as securities / financial instruments or deemed illeg al in the Purchaser’s respective jurisdiction. The Purchaser is obliged to verify whether the acquisition and disposal of the Tokens is legal in their jurisdiction, and by accepting the provisions of this Terms, the Purchaser agrees not to use the Tokens in case their use is considered not legal.
Sample 1
LEGAL AND REGULATORY FRAMEWORK. 2.1 Much of the information needing to be shared in safeguarding work will be confidential and sensitive personal information and regulated by: the Data Protection Act 1998 the common law duty of confidentiality the Human Rights Act 1998 and European Convention on Human Rights, in particular Article 8 (the right to respect for private and family life) the Access to Health Records Act 1990 the Mental Capacity Act 2005 In addition there are a number of professional codes of conduct on confidentiality. Confidentiality must not, however, be confused with secrecy and in certain circumstances it will be necessary to exchange or disclose personal information with or without the consent of the subject. The Data Protection Act does not define ‘consent’ but the test to determine the level of understanding of the individual could be based on an application of the ability to give consent in the EU directive on data protection, which defines consent as ‘any freely given specific and informed indication of his wishes by which the data subject signifies his agreement to personal data about him being processed’ Where disclosure is necessary to comply with a legal obligation imposed on an organisation by statute or by the courts, then the consent of the subject is not necessary. In other cases, public interest arguments may have to apply to the breach of confidence in order to prevent risk of injury or harm to vulnerable adults or to others. Provisions of the Crime and Disorder Act 1998 encourage the effective sharing of material in the interests of reducing crime and disorder and complement the public interest obligation for public agencies to co-operate with the detection and prevention of serious crime. Section 115 of the Act allows any person, who otherwise would not have the power to disclose information to the police, local authority, probation or health authority and guidance form the Information Commissioner suggests that this power can be used to support anti-crime initiatives by these agencies generally. There are statutory restrictions on passing on certain types of information concerned with venereal disease, human fertilisation and embryology and abortion. If it seems likely that information to be shared falls within any of these categories then further specialist advice should be sought.
Sample 1
LEGAL AND REGULATORY FRAMEWORK. The City and ComEd exist within a legal and regulatory framework that governs the topics in this Agreement. ComEd is a public utility under state and federal law and an Illinois public and electric utility, and as such, is subject to extensive regulation and oversight by, among others, the State of Illinois, including but not limited to the ICC, and the United States government, including but not limited to the Federal Energy Regulatory Commission (“FERC”), and bodies established or regulated by federal and State law. Notwithstanding anything herein to the contrary, all activities undertaken under this Agreement including, without limitation, the funding of programs and projects, the provision of utility services, and any changes in utility services, rates, rate designs, policies, or practices must be consistent with and implemented in accordance with such laws and regulations. Without limiting the foregoing: (a) The Parties acknowledge that in carrying out this Agreement, there may be ICC or other Competent Authority approvals (including without limitation, for the full recovery of costs associated with the programs, initiatives, etc. in rates) that, in ComEd’s judgment, become necessary and ComEd’s commitments in carrying out projects and initiatives developed in accordance with this Agreement (including the initiatives described in Section 6 and Exhibit A) are contingent on receipt of ICC or other Competent Authority approvals. The City agrees to cooperate with and support ComEd’s efforts to obtain the necessary approvals of the ICC or other Competent Authorities in connection with this Agreement. For the avoidance of doubt, this obligation to cooperate and support does not limit the City’s right to participate or take any position in other proceedings before the ICC or any other Competent Authority. (b) The Parties acknowledge that ComEd has entered into a three-year Deferred Prosecution Agreement (“DPA”) on July 17, 2020 with the United States Attorney for the Northern District of Illinois. Nothing in this Agreement shall require ComEd to take any action that, in ComEd’s judgment, may cause ComEd to violate, or cause it to come into conflict with the spirit or intent of, the DPA.
Sample 1

Related to LEGAL AND REGULATORY FRAMEWORK

  • Legal and Regulatory Actions Contractor represents and warrants that it is not aware of and has received no notice of any court or governmental agency proceeding, investigation, or other action pending or threatened against Contractor or any of the individuals or entities included in numbered paragraph 1 of these Contract Affirmations within the five (5) calendar years immediately preceding execution of this Contract or the submission of any related Solicitation Response that would or could impair Contractor’s performance under this Contract, relate to the contracted or similar goods or services, or otherwise be relevant to System Agency’s consideration of entering into this Contract. If Contractor is unable to make the preceding representation and warranty, then Contractor instead represents and warrants that it has provided to System Agency a complete, detailed disclosure of any such court or governmental agency proceeding, investigation, or other action that would or could impair Contractor’s performance under this Contract, relate to the contracted or similar goods or services, or otherwise be relevant to System Agency’s consideration of entering into this Contract. In addition, Contractor acknowledges this is a continuing disclosure requirement. Contractor represents and warrants that Contractor shall notify System Agency in writing within five (5) business days of any changes to the representations or warranties in this clause and understands that failure to so timely update System Agency shall constitute breach of contract and may result in immediate contract termination.

  • Clinical Data and Regulatory Compliance The preclinical tests and clinical trials, and other studies (collectively, “studies”) that are described in, or the results of which are referred to in, the Registration Statement or the Prospectus were and, if still pending, are being conducted in all material respects in accordance with the protocols, procedures and controls designed and approved for such studies and with standard medical and scientific research procedures; each description of the results of such studies is accurate and complete in all material respects and fairly presents the data derived from such studies, and the Company and its subsidiaries have no knowledge of any other studies the results of which are inconsistent with, or otherwise call into question, the results described or referred to in the Registration Statement or the Prospectus; the Company and its subsidiaries have made all such filings and obtained all such approvals as may be required by the Food and Drug Administration of the U.S. Department of Health and Human Services or any committee thereof or from any other U.S. or foreign government or drug or medical device regulatory agency, or health care facility Institutional Review Board (collectively, the “Regulatory Agencies”); neither the Company nor any of its subsidiaries has received any notice of, or correspondence from, any Regulatory Agency requiring the termination, suspension or modification of any clinical trials that are described or referred to in the Registration Statement or the Prospectus; and the Company and its subsidiaries have each operated and currently are in compliance in all material respects with all applicable rules, regulations and policies of the Regulatory Agencies.

  • Research and Development (i) Advice and assistance in relation to research and development of Party B; (ii) Advice and assistance in strategic planning; and

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!